NCT07762092 · NOT YET RECRUITING
A Post Authorization Registry Study of Participants Treated With LEQEMBI
This is a post-approval registry study — not a clinical trial testing whether Leqembi works, but an ongoing safety watch now that the drug is in use. Researchers in Canada are tracking real-world patients on Leqembi to record how often serious side effects occur, especially ARIA — brain swelling and microbleeds — and large brain hemorrhages. No phase is assigned because this is observational, not experimental.
You may qualify if
- Participants with Alzheimer's Disease who are prescribed LEQEMBI in Canada.
You're excluded if
- None
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-08-13